COMPANY HISTORY

Overview

NanoMab Technology Ltd was founded in 2016 by Dr. Hong Hoi Ting and Mr. Henry Ho following a collaboration with Professor Yakun Wan, an expert in the development of camelid single domain antibodies.

The company established its main operating site in Shanghai, PRC where it continues to have its major scientific activities. In 2018, the company set up a collaboration with King’s College London and the following year began to work with the University Hospital in Aachen. In June 2019, NanoMab entered into a commercial agreement with LantheusMedical Imaging Inc.

In 2020, NanoMab set up an operation in the UK ahead of transferring its headquarters to London.

2020

Platform built and EU clinical Phase 1&2

NM-01
• EU Phase 1&2 Q4 2020

NM-02 therapeutic
• FIH trial scheduled for Q4 2020

NM-03, 04,05
• Product development commenced (Q1 2020)

Company relocates operations to the UK

2019

NM-01 human trials commenced (PRC)
•PD-L1 SPECT-CT 29 patients
•PD-L1 PET-CT 4 patients

NM-02 imaging human trials commenced
•FIH HER2 SPECT-CT 9 patients

Commercial agreement: Global agreement signed with Lantheus Medical Imaging Inc. for development of NM-01 for clinical research.

2018

Patient testing: First in human (FIH) trial at a PRC 3A hospital, scientific publication in collaboration with
King’s College, London (Results published)

2017

Animal in-vivo trials, production preparation/optimisation, product stability, patent application

2016

Early testing: Team formation, early product samples and in vitro test

2015

Drug target planning & design by HK & PRC scientists (Incubation)